Global Catheter-Related Bloodstream Infection Drugs Market - 2023-2030

Global Catheter-Related Bloodstream Infection Drugs Market - 2023-2030

Global Catheter-Related Bloodstream Infection (CRBSI) drugs market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.

Catheter-related bloodstream infection is a serious and potentially life-threatening condition caused by a variety of microorganisms. These infections occur when microorganisms, including bacteria, fungi, viruses, and parasites, enter the bloodstream through a catheter, such as an intravenous (IV) line or a central venous catheter. These infections pose a significant risk in healthcare facilities and can lead to complications, including sepsis.

The primary treatment for CRBSI involves administering antibiotics to target the specific pathogens responsible for the infection. Commonly used antibiotics for CRBSI include vancomycin, cefazolin, or other agents depending on the identified bacteria and their susceptibility to antibiotics. It is crucial to diagnose and treat CRBSI promptly to minimize its potential complications and risks.

Market Dynamics: Drivers and Restraints

The increasing prevalence of catheter-related bloodstream infections (CRBSI) is expected to drive market growth. According to the National Center for Biotechnology Information Article published in 2021, stated that Catheter-related bloodstream infections (CRBSI) are a significant clinical problem in hospitals. This issue is constantly evolving due to changes in the population at risk, the spectrum of available pathogens, and an increased use of broad-spectrum antibiotics.

Moreover, according to the National Nosocomial Infections Surveillance (NNIS) system of the Centers for Disease Control and Prevention (CDC), the median rate of Central Line-Associated Bloodstream Infection (CRBSI) in all types of intensive care units (ICUs) ranges from 1.8 to 5.2 per 1000 catheter-days, with an average rate of about 25.6%.

Furthermore, the increasing product launches of drugs, growing acquisitions and collaborations among market players are the other factors expected to drive the market over the forecast period.

Restraint:

The increasing prevalence of antibiotic-resistant strains of bacteria complicates the treatment of CRBSI, lack of awareness among the general public about CRBSI and its treatment options and limited research and development of drugs are the factors expected to hamper the market over the forecast period.

For more details on this report – Request for Sample

Segment Analysis

The global catheter-related bloodstream infection (CRBSI) drugs market is segmented based on causative organisms, drug class, route of administration, distribution channel and region.

The antibiotics from the drug class segment accounted for approximately 45.4% of the catheter-related bloodstream infection (CRBSI) drugs market share

Antibiotics play a pivotal role in the management of catheter-related bloodstream infections (CRBSI), offering several advantages in the treatment of this potentially life-threatening condition. These advantages are complemented by a range of drug classes with specific drugs tailored to address different aspects of CRBSI, making them a crucial component in patient care.

Antibiotics in the context of CRBSI provide several benefits. First and foremost, they are effective in targeting the microorganisms responsible for the infection, which are often bacteria like Staphylococcus aureus and Escherichia coli. Antibiotics help to eliminate or suppress these pathogens, reducing the risk of sepsis and other serious complications associated with CRBSI. They also aid in alleviating the clinical symptoms of infection, such as fever and inflammation.

Moreover, antibiotics can be administered intravenously, which is particularly advantageous for patients with CRBSI, as it ensures rapid and reliable drug delivery to the bloodstream, directly addressing the source of infection within the catheter. Furthermore, by mitigating CRBSI, antibiotics help reduce the length and cost of hospital stays, benefiting both patients and healthcare facilities.

The market for antibiotics in CRBSI is driven by several precise factors. The high incidence of CRBSI in healthcare settings, emphasises the continual demand for effective antibiotics. The evolution of antibiotic resistance among CRBSI-causing pathogens necessitates the development of new and more potent drugs to overcome these challenges. Therefore, these factors collectively contribute to the development and expansion of the market for antibiotics in the context of CRBSI.

Geographical Analysis

North America accounted for approximately YY% of the market share in 2022

North America is expected to hold the largest market share, owing to the increasing product launches, growing FDA approvals, increasing clinical trials of drugs, and presence of key players in the region.

For instance, on August 29, 2023, Hikma Pharmaceuticals PLC launched Vancomycin Hydrochloride (HCl) for Injection, USP, with a dosage of 1.25g and 1.5g. The multinational pharmaceutical company has launched this product in the US to treat a range of infections, including septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections. The drug is specially meant for patients who are unable to receive or have not responded to other drugs like penicillins or cephalosporins. It is effective against methicillin-resistant Staphylococcus aureus (MRSA) and coagulase-negative staphylococci infections.

Moreover, on April 4, 2023, Baxter International Inc., a worldwide leader in the production and delivery of sterile medication, launched ZOSYN (piperacillin and tazobactam) Injection in the United States. ZOSYN premix is meant for the treatment of various infections caused by susceptible bacteria, and it is available in Baxter's single-dose Galaxy containers.

Additionally, on April 24, 2023, Citius Pharmaceuticals, Inc. is developing and selling first-in-class critical care products. The company made progress in its clinical trial for Mino-Lok - an antibiotic lock solution to save catheters in patients with catheter-related bloodstream infections. Hence, owing to the above factors, the North American region is expected to hold the largest market share over the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted the catheter-related bloodstream infection (CRBSI) drug market. The COVID-19 pandemic has brought a global focus on infection prevention and control, which includes preventing catheter-related bloodstream infections (CRBSI). This heightened awareness has led to an increased emphasis on CRBSI drugs as an essential component of healthcare.

The urgent need to find treatments and preventions for COVID-19 has resulted in significant investments in research and development in the pharmaceutical and biotechnology industries. This influx of resources has indirectly benefited the CRBSI drugs market since many of the same companies produce drugs that are relevant to CRBSI.

Due to the overwhelming number of COVID-19 patients, hospitals were inundated, and non-essential procedures were postponed, resulting in a decrease in the placement of catheters and related procedures. As a result, the demand for CRBSI drugs also reduced.

In contrast, a retrospective study has shown that the COVID-19 pandemic has led to an increase in catheter-related bloodstream infections. This is mainly because hospitals have been treating sicker patients who require longer and more frequent use of catheters and ventilators. In addition to this, hospitals have also been facing challenges in terms of supply shortages, reduced staffing, and longer visits during the pandemic. Therefore, the COVID-19 pandemic had both negative and positive effects on the market for drugs used to treat catheter-related bloodstream infections (CRBSI).

Market Segmentation:

By Causative Organisms
• Bacterial Infections
• Fungal Infection
• Viral and Parasitic Infections

By Drug Class
• Antibiotics
Ampicillin
Piperacillin
Ciprofloxacin
Levofloxacin
Vancomycin
Daptomycin
Others
• Antifungals
Fluconazole
Caspofungin
Micafungin
Anidulafungin
Others
• Antivirals
Acyclovir
Ganciclovir
Others
• Others

By Route of Administration
• Oral
• Injectable

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the catheter-related bloodstream infection drugs market include Hikma Pharmaceuticals PLC, Zhejiang Novus Pharmaceuticals Co., Ltd., Pfizer, Inc., SteriMax, Baxter, Fresenius Kabi USA, Merck & Co., Inc., Xellia Pharmaceuticals, AdvaCare Pharma, and Avet Pharmaceuticals Inc. among others.

Key Development
• On April 4, 2023, Baxter International Inc., a worldwide leader in the production and delivery of sterile medication, launched ZOSYN (piperacillin and tazobactam) Injection in the United States. ZOSYN premix is meant for the treatment of various infections caused by susceptible bacteria, and it is available in Baxter's single-dose Galaxy containers.
• On August 29, 2023, Hikma Pharmaceuticals PLC launched Vancomycin Hydrochloride (HCl) for Injection, USP, with a dosage of 1.25g and 1.5g. The multinational pharmaceutical company has launched this product in the US to treat a range of infections, including septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections. The drug is specially meant for patients who are unable to receive or have not responded to other drugs like penicillins or cephalosporins. It is effective against methicillin-resistant Staphylococcus aureus (MRSA) and coagulase-negative staphylococci infections.

Why Purchase the Report?
• To visualize the global catheter-related bloodstream infection drugs market segmentation based on causative organisms, drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of catheter-related bloodstream infection (CRBSI) drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global catheter-related bloodstream infection drugs market report would provide approximately 69 tables, 67 figures, and 189 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies